{"nctId":"NCT01969721","briefTitle":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","startDateStruct":{"date":"2013-10"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":229,"armGroups":[{"label":"T+O FDC dosage 1","type":"EXPERIMENTAL","interventionNames":["Drug: olodaterol","Drug: placebo","Drug: tiotropium"]},{"label":"T+O FDC dosage 2","type":"EXPERIMENTAL","interventionNames":["Drug: placebo","Drug: tiotropium","Drug: olodaterol"]},{"label":"ICS/LABA FDC Dosage 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: fluticasone propionate","Drug: salmeterol","Drug: placebo"]},{"label":"ICS/LABA FDC Dosage 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: placebo","Drug: fluticasone propionate","Drug: salmeterol"]}],"interventions":[{"name":"fluticasone propionate","otherNames":[]},{"name":"salmeterol","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"olodaterol","otherNames":[]},{"name":"olodaterol","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"fluticasone propionate","otherNames":[]},{"name":"salmeterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of chronic obstructive pulmonary disease\n2. Relatively stable airway obstruction with a post-bronchodilator 30% \\</= Forced Expiratory Volume in 1 second (FEV1)\\<80% of predicted normal and a post-bronchodilator FEV1/(Forced Vital Capacity)FVC \\<70%\n3. Male or female patients, 40 years of age or older\n4. Smoking history of more than 10 pack years\n5. Ability to perform technically acceptable pulmonary function tests and maintain records\n6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler, Accuhaler and from a metered dose inhaler (MDI)\n\nExclusion criteria:\n\n1. Significant disease other than COPD\n2. COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or iv) or hospitalization in the last 3 months.\n3. Clinically relevant abnormal lab values\n4. History of asthma\n5. Diagnosis of thyrotoxicosis\n6. Diagnosis of paroxysmal tachycardia\n7. History of myocardial infarction\n8. Unstable or life-threatening cardiac arrhythmia\n9. Hospitalization for heart failure within the past year\n10. Known active tuberculosis\n11. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years\n12. History of life-threatening pulmonary obstruction\n13. History of cystic fibrosis\n14. Clinically evident bronchiectasis\n15. History of significant alcohol or drug abuse\n16. History of thoracotomy with pulmonary resection\n17. oral or patch ß-adrenergics\n18. Oral corticosteroid medication within 6 weeks prior to Visit 1\n19. Regular use daytime oxygen therapy for more than one hour per day\n20. Pulmonary rehabilitation program in the six weeks prior to the screening visit\n21. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit\n22. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA\n23. Pregnant or nursing women","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"FEV1 AUC (0-12h) Change From Patient Baseline After 6 Weeks of Treatment","description":"Change from patient baseline in Forced Expiratory Volume in one second (FEV1) Area Under the FEV1-time Curve from 0 to 12hours post-dose (AUC 0-12h) \\[L\\] after 6 weeks of treatment. Measured values presented are actually adjusted means.\n\nThe period baseline is defined as the pre-dose measurement taken at on the day 1 of each period. The patient baseline is defined as the mean of non-missing period baselines for each patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.295","spread":"0.014"},{"groupId":"OG001","value":"0.317","spread":"0.014"},{"groupId":"OG002","value":"0.192","spread":"0.015"},{"groupId":"OG003","value":"0.188","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC (0-24h) Change From Patient Baseline After 6 Weeks of Treatment","description":"Change from patient baseline in Forced Expiratory Volume in one second (FEV1) Area Under the FEV1-time Curve from 0 to 24 hours post-dose (AUC 0-24h) \\[L\\] after 6 weeks of treatment.\n\nMeasured values presented are actually adjusted means. The period baseline is defined as the pre-dose measurement taken at on the day 1 of each period. The patient baseline is defined as the mean of non-missing period baselines for each patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.228","spread":"0.014"},{"groupId":"OG001","value":"0.244","spread":"0.014"},{"groupId":"OG002","value":"0.162","spread":"0.014"},{"groupId":"OG003","value":"0.159","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Change From Patient Baseline After 6 Weeks of Treatment","description":"Change from patient baseline in Trough Forced Expiratory Volume in one second (FEV1) after 6 weeks of treatment. Trough FEV1 was defined as the mean of the 23h and 23h 50min (minutes) post-dose FEV1 measurements. Measured values presented are actually adjusted means.\n\nThe period baseline is defined as the pre-dose measurement taken at on the day 1 of each period. The patient baseline is defined as the mean of non-missing period baselines for each patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.192","spread":"0.014"},{"groupId":"OG001","value":"0.197","spread":"0.014"},{"groupId":"OG002","value":"0.150","spread":"0.014"},{"groupId":"OG003","value":"0.139","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC (12-24h) Change From Patient Baseline After 6 Weeks of Treatment","description":"Change from patient baseline in Forced Expiratory Volume in one second (FEV1) Area Under the FEV1-time Curve from 12 to 24 hours post-dose (AUC 12-24h) \\[L\\] after 6 weeks of treatment. Measured values presented are actually adjusted means.\n\nThe period baseline is defined as the pre-dose measurement taken at on the day 1 of each period. The patient baseline is defined as the mean of non-missing period baselines for each patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.160","spread":"0.014"},{"groupId":"OG001","value":"0.172","spread":"0.014"},{"groupId":"OG002","value":"0.132","spread":"0.014"},{"groupId":"OG003","value":"0.129","spread":"0.014"}]}]}]},{"type":"SECONDARY","title":"FEV1 Peak (0-3h) Change From Patient Baseline After 6 Weeks of Treatment","description":"Change from patient baseline in Forced Expiratory Volume in one second (FEV1) peak (0-3 hours) after 6 weeks of treatment. FEV1 peak (0-3 hours) was defined as the maximum FEV1 value measured within the first three hours post dosing. Measured values presented are actually adjusted means.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.401","spread":"0.016"},{"groupId":"OG001","value":"0.432","spread":"0.016"},{"groupId":"OG002","value":"0.291","spread":"0.016"},{"groupId":"OG003","value":"0.285","spread":"0.015"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":215},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis"]}}}